Valuation: Incyte Corporation

Market Cap 23.37B 122B 20.77B 19.36B 17.65B 33.3B 2,251B 33.61B 235B 90.96B 1,148B 87.74B 85.84B 3,689B P/E 2026 *
54x
P/E 2027 * 15.9x
Enterprise Value 19.1B 99.72B 16.97B 15.82B 14.42B 27.21B 1,839B 27.46B 192B 74.32B 938B 71.69B 70.13B 3,014B EV / Sales 2026 *
3.21x
EV / Sales 2027 * 2.78x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-3.99%
1 week-8.34%
Current month-8.34%
1 month-6.90%
3 months+0.53%
6 months+23.49%
Current year+7.73%
1 week 298.53
Extreme 298.53
310.93
1 month 298.53
Extreme 298.53
326.7
Current year 232.56
Extreme 232.56
328.68
1 year 232.56
Extreme 232.56
328.68
3 years 135.9
Extreme 135.9
328.68
5 years 135.9
Extreme 135.9
328.68
10 years 135.9
Extreme 135.9
328.68
Manager TitleAgeSince
Chief Executive Officer 58 2025-06-25
Director of Finance/CFO 57 2026-05-03
President 62 2023-06-04
Director TitleAgeSince
Chairman 59 2025-06-25
Director/Board Member 72 2015-01-19
Director/Board Member 64 2015-01-19
Change 5-day change 1-year change 3-year change Capi.($)
-3.99%-8.34% - - 23.37B
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -1.08%-3.39%+27.17%+57.15% 410.8B
Weighted average by Cap. -0.62%-3.33%+30.52%+68.96%

Financials

2026 *2027 *
Net sales 5.94B 31.02B 5.28B 4.92B 4.49B 8.46B 572B 8.54B 59.65B 23.12B 292B 22.3B 21.82B 937B 6.26B 32.68B 5.56B 5.18B 4.73B 8.92B 603B 9B 62.85B 24.36B 307B 23.49B 22.99B 988B
Net income 445M 2.32B 395M 369M 336M 634M 42.84B 640M 4.47B 1.73B 21.85B 1.67B 1.63B 70.21B 1.5B 7.85B 1.34B 1.25B 1.14B 2.14B 145B 2.16B 15.1B 5.85B 73.85B 5.65B 5.52B 237B
Net Debt -4.28B -22.33B -3.8B -3.54B -3.23B -6.09B -412B -6.15B -42.94B -16.64B -210B -16.05B -15.7B -675B -5.96B -31.13B -5.3B -4.94B -4.5B -8.49B -574B -8.57B -59.86B -23.2B -293B -22.38B -21.89B -941B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
26-10-02 R$298.53 -3.99% 900
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
115.30USD
Average target price
128.42USD
Spread / Average Target
+11.38%

Quarterly revenue - Rate of surprise